

**COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING
Capital Annex -Room 113**

700 Capital Avenue Frankfort, Kentucky 40601

Thursday, September 17, 2009
1:00 P.M. to 5:00 P.M

AGENDA

- I. Roll Call and Call to Order
- II. Welcome and Introductions
- III. Approval of Minutes: July 16, 2009 Meeting
- IV. Vice Chair Nominations
- V. Old Business
 - a. Branded Products with Generic Components
 - i. IC400[®]
 - ii. IC800[®]
 - iii. Benziq[®]
- VI. New Business
 - a. New Products to Market
 - i. Lamictal XR[™]
 - ii. Multaq[®]
 - iii. Cetraxal[™]
 - iv. BenzaClin CareKit[®]
 - v. Nucynta[™]
 - vi. Edluar[®]
 - vii. Adcirca[™]
 - viii. Acuvail[™]
 - ix. Effient[™]
 - b. New Class Reviews
 - i. Protein Tyrosine Kinase Inhibitors
 - c. Clinical Criteria Reviews
 - i. Ranexa[™] Clinical Criteria
 - ii. Lidoderm[®] Clinical Criteria
 - d. Existing Class Reviews
 - i. Hepatitis C: Pegylated Interferons
 - ii. Hepatitis C: Pegylated Interferons Clinical Criteria
 - iii. Hepatitis C: Ribavirins
 - iv. Hepatitis C: Ribavirins Clinical Criteria
 - v. Antihyperkinesis Agents
 - vi. Antihyperkinesis Agents Clinical Criteria
 - vii. Antihyperkinesis Agents, Special Formulations Clinical Criteria
 - viii. Strattera[®] Clinical Criteria

- ix. Provigil® / Nuvigil® Clinical Criteria
- x. Calcium Channel Blockers (DHP)
- xi. ACE Inhibitors
- xii. ACE Inhibitor + Diuretic Combinations
- xiii. Antibiotic Agents for Acne
- xiv. Topical Retinoids
- xv. Oral Retinoids
- xvi. Isotretinoin Clinical Criteria
- xvii. Corticosteroids, Intranasal
- xviii. Endocrine and Metabolic Agents
 - 1. Amylin Analog
 - 2. Symlin® Clinical Criteria
 - 3. Incretin Mimetic
 - 4. Byetta™ Clinical Criteria
 - 5. Alpha Glucosidase Inhibitors
 - 6. Biguanides
 - 7. Meglitinides
 - 8. Sulfonylureas and Combinations
 - 9. Thiazolidinediones
 - 10. Thiazolidinedione Combinations
 - 11. Bone: Calcitonins
- xix. Immunologic Agents
 - 1. Immunomodulators
 - 2. Immunomodulator Clinical Criteria
 - 3. Topical Immunomodulators
 - 4. Multiple Sclerosis Agents

VII. Adjournment

- a. Next Meeting-November 19, 2009
- b. Collection of Travel Vouchers

PUBLIC SPEAKERS: If you would like to speak during the public session please complete the Speaker Request Form posted on the Kentucky and First Health websites.